Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?

被引：48
作者：
Kudzi, William [1 ,2 ]
Dodoo, Alexander N. O. [2 ]
Mills, Jeremy J. [1 ]
机构：
[1] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England
[2] Univ Ghana, Sch Med, Accra, Ghana
来源：
BMC MEDICAL GENETICS | 2010年 / 11卷
关键词：
SINGLE-NUCLEOTIDE POLYMORPHISMS; MULTIDRUG-RESISTANCE GENE; ONCHOCERCIASIS-ENDEMIC FOCI; P-GLYCOPROTEIN; TRANSPLANT RECIPIENTS; MULTIPLE TREATMENTS; SEQUENCE DIVERSITY; CYTOCHROME-P450; 3A; LIVER-MICROSOMES; DRUG TRANSPORTER;
D O I：
10.1186/1471-2350-11-111
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Background: Ivermectin, a substrate of multidrug resistance (MDR1) gene and cytochrome P450 (CYP) 3A4, has been used successfully in the treatment of onchocerciasis in Ghana. However, there have been reports of suboptimal response in some patients after repeated treatment. Polymorphisms in host MDR1 and CYP3A genes may explain the observed suboptimal response to ivermectin. We genotyped relevant functional polymorphisms of MDR1 and CYP3A in a random sample of healthy Ghanaians and compared the data with that of ivermectin-treated patients with a view to exploring the relationship between suboptimal response to ivermectin and MDR1 and CYP3A allelic frequencies. Methods: Using PCR-RFLP, relevant polymorphic alleles of MDR1 and CYP3A4 genes were analysed in 204 randomly selected individuals and in 42 ivermectin treated patients. Results: We recorded significantly higher MDR1 (3435T) variant allele frequency in suboptimal responders (21%) than in patients who responded to treatment (12%) or the random population sample (11%). CYP3A4*1B, CYP3A5*3 and CYP3A5*6 alleles were detected at varied frequencies for the sampled Ghanaian population, responders and suboptimal responders to ivermectin. CYP3A5*1/CYP3A5*1 and CYP3A5*1/CYP3A5*3 genotypes were also found to be significantly different for responders and suboptimal responders. Haplotype (*1/*1/*3/*1) was determined to be significantly different between responders and suboptimal responders indicating a possible role of these haplotypes in treatment response with ivermectin. Conclusion: A profile of pharmacogenetically relevant variants for MDR1, CYP3A4 and CYP3A5 genes has been generated for a random population of 204 Ghanaians to address the scarcity of data within indigenous African populations. In 42 patients treated with ivermectin, difference in MDR1 variant allele frequency was observed between suboptimal responders and responders.
引用
收藏
页数：8
相关论文
共 46 条
[1]   Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations [J].
Allabi, AC ;
Gala, JL ;
Desager, JP ;
Heusterspreute, M ;
Horsmans, Y .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :653-657
[2]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[3]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[4]   Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein [J].
Ardelli, BF ;
Guerriero, SB ;
Prichard, RK .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2005, 143 (01) :58-66
[5]   An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana [J].
Awadzi, K ;
Boakye, DA ;
Edwards, G ;
Opoku, NO ;
Attah, SK ;
Osei-Atweneboana, MY ;
Lazdins-Helds, JK ;
Ardrey, AE ;
Addy, ET ;
Quartey, BT ;
Ahmed, K ;
Boatin, BA ;
Soumbey-Alley, EW .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2004, 98 (03) :231-249
[6]   Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana [J].
Awadzi, K ;
Attah, SK ;
Addy, ET ;
Opoku, NO ;
Quartey, BT ;
Lazdins-Helds, JK ;
Ahmed, K ;
Boatin, BA ;
Boakye, DA ;
Edwards, G .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2004, 98 (04) :359-370
[7]   Role of transport proteins in drug absorption, distribution and excretion [J].
Ayrton, A ;
Morgan, P .
XENOBIOTICA, 2001, 31 (8-9) :469-497
[8]   CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations [J].
Balram, C ;
Zhou, QY ;
Cheung, YB ;
Lee, EJD .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) :123-126
[9]   Unmasking the dynamic interplay between efflux transporters and metabolic enzymes [J].
Benet, LZ ;
Cummins, CL ;
Wu, CY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) :3-9
[10]   The current state of the Onchocerciasis Control Programme in West Africa [J].
Boatin, BA .
TROPICAL DOCTOR, 2003, 33 (04) :209-214
12345